Wide Ranks

GOVX

GeoVax Labs, Inc.

2.71

Top Statistics
Market Cap 25 M Forward PE -3.15 Revenue Growth 0.00 %
Current Ratio 0.60 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.4710 Enterprise / Revenue 42.55 Price To Sales Trailing12 Months 85.05
Profitability
Profit Margins 0.00 % Operating Margins -1683.61 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.2970 Total Debt 142292
Total Debt To Equity Current Ratio 0.60 Book Value Per Share 2.92
All Measures
Short Ratio 35.00 % Message Board Id finmb_12056751 Fax 678 384 7281
Shares Short Prior Month 301214 Return On Equity -3.62 City Smyrna
Uuid c7c31a63-264a-3189-a2f8-87643849f80c Previous Close 2.70 First Trade Date Epoch Utc 1 B
Book Value 2.92 Beta 3.11 Total Debt 142292
Volume 440349 Price To Book 0.9297 Last Split Date 1 B
Fifty Two Week Low 1.09 Total Cash Per Share 0.2970 Total Revenue 300677
Shares Short Previous Month Date 1 B Target Median Price 15.00 Max Age 86400
Recommendation Mean 1.40 Sand P52 Week Change 0.3133 Operating Margins -1683.61 %
Target Mean Price 14.20 Net Income To Common -26915400 Short Percent Of Float 0.0355
Implied Shares Outstanding 9 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 1 M
Next Fiscal Year End 1 B Revenue Per Share 0.1430 Held Percent Insiders 0.0052
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.70 Target Low Price 8.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.34 Open 2.70 Free Cashflow -14219356
State GA Dividend Yield 0.00 % Return On Assets -1.34
Time Zone Short Name EST Trailing Eps -8.39 Day Low 2.62
Address1 1900 Lake Park Drive Shares Outstanding 9 M Price Hint 4
Target High Price 20.00 Website https://www.geovax.com 52 Week Change -0.5789
Average Volume 1 M Forward Eps -0.8600 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 29.10 % Last Split Factor 1:15
Regular Market Day High 2.76 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 11.18 Day High 2.76 Shares Short 301021
Regular Market Open 2.70 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 42.55 Revenue Growth 0.00 % Shares Percent Shares Out 0.0353
Operating Cashflow -22998400 Currency USD Time Zone Full Name America/New_York
Market Cap 25 M Is_nasdaq_100 False Zip 30080
Quote Type EQUITY Industry Biotechnology Long Name GeoVax Labs, Inc.
Regular Market Day Low 2.62 Held Percent Institutions 0.1083 Current Price 2.71
Address2 Suite 380 Enterprise To Ebitda -0.4710 Financial Currency USD
Current Ratio 0.60 Industry Disp Biotechnology Number Of Analyst Opinions 5
Country United States Float Shares 5 M Two Hundred Day Average 2.45
Ir Website http://www.geovax.com/investors/stock_chart.php Enterprise Value 12 M Price To Sales Trailing12 Months 85.05
Forward PE -3.15 Regular Market Volume 440349 Ebitda -27155956
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.

It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever.

It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.

S.

Department of Defense; Emory University; and the Burnet Institute.

GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.